As announced in the recently published Q2 interim report, the Board of Directors of Chr. Hansen regrettably announces that CFO Søren Westh Lonning has decided to pursue his career outside of Chr. Hansen as CFO of a private equity backed, non-competitive company. Søren Westh Lonning has been with Chr. Hansen since 2007, and has been the CFO since 2015. He will leave his position at Chr. Hansen after the full-year report of the 2019/20 financial year. A search for a new CFO will begin immediately, and will consider both internal and external candidates.
Mauricio Graber, CEO of Chr. Hansen, said: “Søren has been a valued colleague in Chr. Hansen and a valued member of my leadership team. In his more than 12 years with Chr. Hansen, and the last 5 as CFO, he has left a very positive mark on the company and achieved outstanding results. I want to thank him for his time here, and his leadership and contributions will be missed. Most recently I have valued his contributions in leading the strategy review process together with me and in close collaboration with the corporate leadership team. I wish him the best of luck in the next step in his career.”
Søren Westh Lonning, CFO of Chr. Hansen, said: “I am truly grateful for the opportunities that I have been given in Chr. Hansen, and I will certainly miss many talented colleagues from the entire organization. I leave Chr. Hansen with a sense of accomplishment, and I believe the company is in great shape and with an exciting future ahead. I sincerely value the close collaboration with our CEO Mauricio Graber and the corporate leadership team. ”
Søren Westh Lonning will continue to serve on the Executive Board, together with CEO Mauricio Graber and CSO Thomas Schäfer, for the remainder of his tenure with Chr. Hansen, and his successor will replace him in the Executive Board. The Executive Board is appointed by the Board of Directors and is responsible for the day-to-day management within the guidelines and directions given by the Board of Directors.
科 汉森是一家全球性且具备差异化的生物科技公司，为食品行业、营养行业、制药行业和畜牧业开发天然原料的解决方案。 在科 汉森，我们拥有独特的优势，可通过微生物解决方案推动积极的变革。 在过去超过 150 年的时间里，我们致力于实现可持续的农业、更好的食品以及让全世界更多的人过上更健康的生活。 我们的微生物和发酵技术平台拥有改变规则的潜力，库存广泛且价值重大，包括约 40,000 种微生物菌株。 除了适应客户需求和全球趋势外，我们还将挖掘释放有益菌的力量，以应对食物浪费、全球健康以及抗生素和杀虫剂滥用等全球挑战。 作为全世界最具可持续性的生物技术公司，我们每天影响超过 10 亿人的生活。 受我们的创新传统与对前沿科学的求知驱动，公司宗旨“To grow a better world. Naturally.”体现在我们的所有工作中。
